Latest Diagnostics News

Clarity Pharmaceuticals has expanded its breast cancer pipeline by introducing 64/67Cu-SAR-trastuzumab, supported by promising pre-clinical data and a new supply agreement for trastuzumab, aiming to address the unmet needs in HER2-positive breast cancer treatment.

BlinkLab has secured North Shore Pediatric Therapy as the second US clinical site in its autism diagnostic study, enhancing recruitment and data quality with a leading Chicago-based specialist.

Radiopharm Theranostics' RAD 101 radiotracer demonstrates high sensitivity in detecting brain metastases using a novel PET-mpMRI approach, with a Phase 2b trial now recruiting in the US.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.

ImpediMed Limited has locked in a US$15 million growth capital facility with SWK Funding LLC, providing crucial financial flexibility to advance its SOZO Digital Health Platform and commercial ambitions.

Pro Medicus has inked a $53 million, seven-year contract with BayCare to deploy its Visage 7 cloud-based imaging platform across Florida’s largest healthcare system, marking a major step in its North American expansion.

Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.

Beamtree Holdings appoints Marek Stepniak as CEO, signaling a strategic push in international markets with a strong leadership hand familiar with the company’s growth trajectory.

Optiscan Imaging has initiated a pivotal pre-clinical gastrointestinal study in Germany using its first flexible prototype, aiming to revolutionize real-time GI tract imaging and diagnostics.

Rewardle Holdings reports a strong December quarter with positive cash flow and a significant valuation uplift in its CloudHolter partnership, underpinning its multi-pronged growth strategy.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.